Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]
- Market Cap ₹ 46.6 Cr.
- Current Price ₹ 29.3
- High / Low ₹ 95.0 / 22.7
- Stock P/E
- Book Value ₹ 80.6
- Dividend Yield 0.00 %
- ROCE 8.05 %
- ROE 4.68 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.36 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 35.6%
- Contingent liabilities of Rs.34.6 Cr.
- Debtor days have increased from 36.2 to 44.8 days.
- Promoter holding has decreased over last 3 years: -14.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 369 | 318 | 238 | |
| 351 | 282 | 237 | |
| Operating Profit | 17 | 36 | 1 |
| OPM % | 5% | 11% | 1% |
| 0 | 0 | 0 | |
| Interest | 14 | 15 | 17 |
| Depreciation | 15 | 17 | 18 |
| Profit before tax | -11 | 5 | -34 |
| Tax % | -18% | -41% | |
| -9 | 7 | -31 | |
| EPS in Rs | -5.73 | 4.25 | -19.54 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -404% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -25% |
| 3 Years: | -36% |
| 1 Year: | -64% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 16 | 16 | 16 |
| Reserves | 120 | 133 | 112 |
| 107 | 96 | 95 | |
| 91 | 121 | 94 | |
| Total Liabilities | 334 | 366 | 317 |
| 148 | 163 | 159 | |
| CWIP | 8 | 3 | 4 |
| Investments | 0 | 0 | 0 |
| 178 | 201 | 155 | |
| Total Assets | 334 | 366 | 317 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 4 | 43 | |
| -12 | -19 | |
| 5 | -22 | |
| Net Cash Flow | -3 | 1 |
| Free Cash Flow | -8 | 23 |
| CFO/OP | 23% | 118% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 28 | 45 |
| Inventory Days | 185 | 303 |
| Days Payable | 99 | 199 |
| Cash Conversion Cycle | 113 | 149 |
| Working Capital Days | 11 | 5 |
| ROCE % | 8% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Spend INR Lakhs ・Standalone data |
|
|||||||||||
| Sale of Products (API/Intermediates) INR Lakhs ・Standalone data |
||||||||||||
| Total Number of Employees Count ・Standalone data |
||||||||||||
| Export Turnover INR Lakhs ・Standalone data |
||||||||||||
| Number of WHO Approved DMFs Count ・Standalone data |
||||||||||||
| Number of Research Scientists Count ・Standalone data |
||||||||||||
| Manufacturing Capacity - APIs TPA ・Standalone data |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
17 Apr - Ms. Anuradha Pandey resigned as Company Secretary and Compliance Officer, effective 29 March 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
17 Apr - Company Secretary and Compliance Officer Anuradha Pandey resigned, effective 29 March 2026.
-
Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure
16 Apr - Company disclosed 30-day-plus default on Bank of Maharashtra and Bank of Baroda loans of Rs 951.97 lakh and Rs 606.08 lakh.
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Submission of Compliance Certificate received from RTA under Regulation 74(5) of SEBI(DP) Regulations, 2018
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
Business Overview:[1]
MDOL (formerly Advent Pharma Pvt Ltd) is a part of the Mangalam group. The co manufactures bulk drugs, and organic and inorganic chemicals. It is among the few companies which are World Health Org.approved Indian companies to be associated
with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs. MDOL supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.